Per report received from japan, the patient underwent a transfemoral transcatheter aortic valve replacement (tavr) and received a 26 mm sapien 3 ultra resilia (s3ur) valve.When inflating the balloon of the commander delivery system (ds) to deploy the s3ur valve, resistance was felt, and a pressure gauge of an atrion inflation device (atrion) indicated 9-10atm.The valve was deployed with 1 ml less than nominal volume and landed 80:20 aortic/ventricular position as intended.The inflation time was the same as normal cases, and paravalvular leak (pvl) was mild.Post dilation was not performed due to the native valve calcification and the inflation resistance.After withdrawing the ds from the patient, the doctor inflated the balloon of the ds to check the ds and atrion.Inflation resistance was felt again and the atrion indicated 7-8atm.There was no patient injury or contrast medium leakage reported.Per follow-up information, the patient recovered without problems.
|
A supplemental mdr is being submitted due to product evaluation findings.Sections b4, d9, g3, g6, h2, h3, h6: type of investigation, investigation findings, investigation conclusions and h10 has been updated.The device was returned to edwards lifesciences for evaluation.The visual inspection of the returned device revealed the following: device was kinked/twisted at the proximal balloon shaft of delivery system; the pressure gauge needle was in the zero position.The device was functionally tested and the following was observed: the returned atrion inflation device was tested with sample commander delivery system; atrion inflation device was able to meet inflation/ deflation time specification; the device was within gauge tolerance accuracy testing at 4, 14 and 30 atm; the device passed pressure leak testing, pressure decay testing and vacuum capability testing with no anomalies noted.Due to the nature of the complaint, no applicable dimensional testing was able to be performed.The complaint for "inflation difficulty" is not confirmed as the alleged physical defect is not present on the returned device.An engineering evaluation is not required.No evidence of product non-conformances or labeling/ifu inadequacies were identified in the evaluation.Current risk mitigations include design and manufacturing controls, ifu warnings and cautions, and physician training on how to deploy thv.The benefits of the device outweigh the risks associated with difficult or unable to inflate balloon, resulting in procedural delay.The ifu and training manuals have been reviewed and no inadequacies have been identified with regards to warnings, contraindications, and the directions/conditions for the successful use of the device.Complaint histories for all reported events are reviewed against trending control limits monthly, and any excursions above the control limits are assessed and documented as part of this monthly review.
|